Lung Cancer Clinical Trial
Official title:
Evaluation of the Safety and Effectiveness of Percutaneous and Transbronchial Argon-helium Cryoablation
The goal clinical trial is to evaluation of the safety and effectiveness of percutaneous and transbronchial argon-helium cryoablation in primary lung cancer and metastatic lung cancer. The main question it aims to answer are:Evaluation of the safety and effectiveness of percutaneous and transbronchial argon-helium cryoablation. Participants will undergo percutaneous or transbronchial argon-helium cryoablation.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: - Primary or metastatic lung cancer with definite pathological diagnosis - Not suitable for thoracotomy due to serious or serious lung or systemic diseases - Peripheral lung cancer involves pleura and chest wall, and cannot be completely removed after surgery - There are indications for surgical resection, but the patient refuses to operate - Single tumor, maximum diameter = 5cm - Or the number of tumors = 3 and the maximum diameter = 3cm - ECOG-PS score = 2 - The expected survival period is more than three months - Those who have not participated in other clinical verifications within 3 months - Subjects voluntarily signed the informed consent form Exclusion Criteria: - Serious cardio-cerebral disease or other mental diseases - Severe pulmonary fibrosis, especially drug-induced pulmonary fibrosis - Patients with previous severe pulmonary dysfunction, pulmonary ventilation disorder and multiple pulmonary bullae - Have a history of immunodeficiency, including HIV test (enzyme-linked immunosorbent assay and Western blotting) positive - Chemotherapy, radiotherapy, interventional therapy, ablation and surgical treatment within 30 days before surgical treatment - There is a tendency to severe bleeding, and the platelet is less than 50 × 109/L and severe disorder of coagulation function - Coagulation index (PT, TT, APTT)>2.5 times of the upper normal limit - Malignant pleural effusion on the same side of the ablation focus was not well controlled - Poor general condition, multiple organ failure, cachexia, severe anemia and nutritional metabolism disorder - Those who have extensive extrapulmonary metastasis and are not suitable for ablation treatment - Those who often use sedatives, sleeping pills, tranquilizers or other addictive drugs - Pregnant or lactating women - Those who can not judge the curative effect - Other conditions determined by the researcher to be unsuitable for the group, such as inability to tolerate cryoablation, difficulty in follow-up, and other serious diseases |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
China-Japan Friendship Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete response rate and effective rate of target lesions | Enhanced imaging examination (CT, MRI or color Doppler ultrasound) | during the operation of argon-helium cryoablation | |
Primary | Complete response rate and effective rate of target lesions | Enhanced imaging examination (CT, MRI or color Doppler ultrasound) | 1 week after the operation of argon-helium cryoablation | |
Primary | Complete response rate and effective rate of target lesions | Enhanced imaging examination (CT, MRI or color Doppler ultrasound) | 4 weeks(±7d) after the operation of argon-helium cryoablation | |
Secondary | the iceball coverage rate during the procedure | CT | during the procedure | |
Secondary | Subjects' tolerance of the procedure | questionnaire | 1 week after the operation of argon-helium cryoablation | |
Secondary | the Eastern Cooperative Oncology Group Performance Status (ECOG PS) score | ECOG-PS questionnaire | 4 weeks(±7d) after the operation of argon-helium cryoablation | |
Secondary | To evaluate the operational performance of argon-helium cryoablation | questionnaire | during the procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|